This double-blind placebo-controlled microdosing study (n=56) explored the effects of four repeated doses of LSD (13 or 26μg) on measures of mood and cognition. LSD administration sessions were separated by 3-4 days. LSD (26μg) produced modest subjective effects but did not improve mood or affect performance. While LSD was safely administered, low doses of LSD produced negligible changes in mood or cognition in healthy volunteers.
“The resurgence of interest in using psychedelic drugs, including lysergic acid diethylamide (LSD), in psychiatry has drawn attention to the medically unsupervised practice of ‘microdosing’. Thousands of users claim that very low doses of LSD, taken at 3–4-day intervals, improve mood and cognitive function., However, few controlled studies have described the effects of the drug when taken in this way. Here, in a double-blind controlled study, we studied the effects of four repeated doses of LSD tartrate (13 or 26 μg) or placebo, administered to healthy adults at 3–4 day intervals, on mood, cognitive performance and responses to emotional tasks. Participants were randomly assigned to one of three drug conditions: placebo (N = 18), 13 μg LSD (N = 19), or 26 μg LSD (N = 19). They attended four 5-hour drug-administration sessions separated by 3–4 days, followed by a drug-free follow-up session 3–4 days after the last session. LSD (26 μg) produced modest subjective effects, including increased ratings of ‘feeling a drug effect’ and both stimulant-like and LSD-like effects, but the drug did not improve mood or affect performance on psychomotor or most emotional tasks. No residual effects were detected on mood or task performance in the drug-free follow-up session. We conclude that within the context of a controlled setting and a limited number of administrations, repeated low doses of LSD are safe but produce negligible changes in mood or cognition in healthy volunteers.”
Authors: Harriet de Wit, Hanna M. Molla, Anya Bershad, Michael Bremmer & Royce Lee
Find this paper
February 1, 2022
Authors associated with this publication with profiles on BlossomHarriet de Wit
Harriet de Wit is a Professor of Psychiatry and Behavioral Neuroscience at the University of Chicago. Her research focuses on the physiological, subjective (i.e., mood-altering), and behavioral effects of drugs in healthy human volunteers.
Institutes associated with this publicationUniversity of Chicago
Research with psychedelics is taking place at the Human Behavioral Pharmacology Lab at the University of Chicago.
The psychedelics given at which dose and how many timesLSD 15 - 26
μg | 1x
The notable measures taken during this studyLSD 13 μg
Persisting Effects Questionnaire
Before (t=0): 1
After (t= 50 minutes): 2
Effect Size: 2.4